2013
DOI: 10.1016/j.ygyno.2013.01.011
|View full text |Cite
|
Sign up to set email alerts
|

Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: A pilot study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
29
2

Year Published

2014
2014
2023
2023

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 43 publications
(33 citation statements)
references
References 12 publications
2
29
2
Order By: Relevance
“…Grade 3-4 hematologic toxicity was seen in about 20% of patients. These observations are encouraging [52,53] and need confirmation in a randomized study.…”
Section: Dose-dense Nact Prior To Ccrtmentioning
confidence: 66%
“…Grade 3-4 hematologic toxicity was seen in about 20% of patients. These observations are encouraging [52,53] and need confirmation in a randomized study.…”
Section: Dose-dense Nact Prior To Ccrtmentioning
confidence: 66%
“…However, our observed response rate after NACT (100% with 40% CR) and overall survival at 3 years (80%) were higher than that described by McCormack et al (70% and 68%, respectively). The 3 year data were not reported by Singh et al, where the median follow-up period was 22 months [27,28].…”
Section: Discussionmentioning
confidence: 84%
“…The question whether NACT or chemoradiation is a more effective treatment is the subject of investigation of the European Organization for Research in Cancer Therapy (EORTC) protocol 55994 (NCT00193739) and is expected to address the role of NACT and chemoradiation in this settings [26]. We compared our results with similar trials available in the literature which have used the chemoradiation approach [27,28]. These two trials have evaluated the dose-dense neoadjuvant chemotherapy (NACT) with paclitaxel and carboplatin before radical chemoradiation (CRT) in locally advanced cervical cancer.…”
Section: Discussionmentioning
confidence: 99%
“…Neoadjuvant chemotherapy compliance was more than 90% in published trials. 11,12 The median (range) number of chemotherapy cycles was 4 (2Y6) in Graham's trial, 5 (1Y8) cycles in Paulson's trial, and 72% of patients received 4 or more cycles in Reed's trial. Rodriguez-Riao et al 13 reported 82.4% for NACT compliance and Nagai et al 14 reported full adherence to NACT.…”
Section: Resultsmentioning
confidence: 99%